RNA interference (RNAi) has increased the possibility
of restoring
RNA drug targets for cancer treatment. Small interfering RNA (siRNA)
is a promising therapeutic RNAi tool that targets the defective gene
by inhibiting its mRNA expression and stopping its translation. However,
siRNAs have flaws like poor intracellular trafficking, RNase degradation,
rapid kidney filtration, off-targeting, and toxicity, which limit
their therapeutic efficiency. Nanocarriers (NCs) have been designed
to overcome such flaws and increase antitumor activity. Combining
siRNA and anticancer drugs can give synergistic effects in cancer
cells, making them a significant gene-modification tool in cancer
therapy. Our discussion of NCs-mediated siRNA delivery in this review
includes their mechanism, limitations, and advantages in comparison
with naked siRNA delivery. We will also discuss organic NCs (polymers
and lipids) and inorganic NCs (quantum dots, carbon nanotubes, and
gold) that have been reported for extensive delivery of therapeutic
siRNA to tumor sites. Finally, we will conclude by discussing the
studies based on organic and inorganic NCs-mediated siRNA drug delivery
systems conducted in the years 2020 and 2021.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.